Heptares Will Work With AstraZeneca | June 6, 2011 Issue - Vol. 89 Issue 23 | Chemical & Engineering News
Volume 89 Issue 23 | p. 25 | Concentrates
Issue Date: June 6, 2011

Heptares Will Work With AstraZeneca

Department: Business
Keywords: pharmaceutical, alliance, discovery, receptors

AstraZeneca and U.K.-based Heptares Therapeutics will collaborate on the discovery and development of compounds targeting G-protein-coupled receptors (GPCRs). Under the four-year deal, AstraZeneca will pay $6.25 million in cash plus research funding to Heptares in exchange for commercial rights to any resulting products. The partners will focus on GPCR targets—which are stabilized for investigation by Heptares’ technology—related to central nervous system, cardiovascular, metabolic, and inflammatory disorders.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment